Compare Gitlab Inc (GTLB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Gitlab Inc trades at $41.57 (market cap $7.11B), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.5× Gitlab Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | REGN | |
|---|---|---|
Market Cap | $7.11B | $82.06B |
Sector | Technology | Health |
52-Week High | $51.04 | $812.27 |
52-Week Low | $19.42 | $555.51 |
Enterprise Value | $5.85B | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
